Clinical Trials Browser

Interventional × VTX-2337 × Genitourinary × Clear all

NCT02650635 2018-09-05

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

Phase 1 Terminated

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms